TY  - JOUR

T1  - Implications and benefits of the NICE appraisal of pembrolizumab

JO  - British Journal of Healthcare Management

PY  - 2015/01/01

AU  - Danson S

ED  - 

DO  - DOI: 10.12968/bjhc.2015.21.11.506

PB  - Mark Allen Group

VL  - 21

IS  - 11

SP  - 506

EP  - 508

Y2  - 2024/09/19

ER  -